

EUROPEAN
CURRICULUM VITAE
FORMAT



PERSONAL INFORMATION

Name **GIUSEPPE LO RUSSO**

Nationality Italian
Date of birth 30 OCTOBER 1982
City of birth CATANZARO (ITA)

WORK EXPERIENCE

- Dates (from – to) **APRIL 2018- SEPTEMBER 2018**
- Name and address of employer The Ohio State University Comprehensive Cancer Center,
College of Medicine, Department of Cancer Biology and Genetics (CBG),
Columbus, Ohio, USA
- Type of business or sector Comprehensive Cancer Center
- Occupation or position held Exchange Visitor
- Main activities and responsibilities Biomedical Research,
Pre-clinical Cancer Research with peculiar interest for Thoracic Tumors

- Dates (from – to) **DECEMBER 2014 - PRESENT**
- Name and address of employer Fondazione IRCCS – Istituto Nazionale Tumori
Milano, Italy
- Type of business or sector Public Hospital
- Occupation or position held Medical Oncologist
- Main activities and responsibilities Clinical management of cancer patients with peculiar interest for Thoracic tumors,
Neuroendocrine tumors, Translational research and Clinical trials

- Dates (from – to) **SEPTEMBER 2012 – JULY 2014**
- Name and address of employer ICOT hospital
Latina, Italy
- Type of business or sector Public Hospital
- Occupation or position held Postgraduate medical training
- Main activities and responsibilities Clinical management of cancer patients, Translational research and Clinical trials

- Dates (from – to) **JULY 2009 – JULY 2014**
- Name and address of employer Distretto 1 ASL Latina
Aprilia, Italy
- Type of business or sector Public Hospital
- Occupation or position held Postgraduate medical training
- Main activities and responsibilities Clinical management of cancer patients, Translational research and Clinical trials

- Dates (from – to)
- Name and address of employer
- Type of business or sector
- Occupation or position held
- Main activities and responsibilities

EDUCATION AND TRAINING

- Dates (from – to)
- Name and type of organisation providing education and training
- Principal subjects/occupational skills covered
- Title of qualification awarded

- Dates (from – to)
- Name and type of organisation providing education and training
- Principal subjects/occupational skills covered
- Title of qualification awarded

- Dates (from – to)
- Name and type of organisation providing education and training
- Principal subjects/occupational skills covered
- Title of qualification awarded

PERSONAL SKILLS AND COMPETENCES

MOTHER TONGUE
OTHER LANGUAGES

- Reading skills
- Writing skills
- Verbal skills

ORGANISATIONAL SKILLS
AND COMPETENCES

JULY 2009 – SEPTEMBER 2012

Santa Maria Goretti Hospital
Latina, Italy
Public Hospital
Postgraduate medical training
Clinical management of cancer patients, Translational research and Clinical trials

DECEMBER 2014 – FEBRUARY 2018

"Sapienza" University of Rome

Translational research

Ph. D. in Medical Oncology

JULY 2009 – JULY 2014

"Sapienza" University of Rome

Clinical Oncology

Specialization in Medical Oncology graduated with honor

SEPTEMBER 2001- MARCH 2008

"Sapienza" University of Rome

Medicine

Degree in Medicine (MD – Medical Doctor) with honor

ITALIAN

ENGLISH

EXCELLENT
EXCELLENT
EXCELLENT

CLINICAL MANAGEMENT OF CANCER PATIENTS

PREPARATION OF RESEARCH PROJECTS

MANAGEMENT OF CLINICAL TRIALS (PHASE I, II AND III) AS SUB-INVESTIGATOR

(EXPERIENCE AS SUB-INVESTIGATOR IN ABOUT 60 CLINICAL TRIALS FOCUSING ON THORACIC TUMORS, AURA 3 FDA INSPECTED)

TECHNICAL SKILLS AND COMPETENCES

OFFICE PACKAGE,
RESEARCH IN PUBLIC DATABASE

RELATIONSHIP SKILLS

GOOD ATTITUDE AND CAPACITY TO WORK IN GROUP
GOOD CAPACITY OF COMMUNICATION

PRIZES AND AWARDS

15.04.2008 PREMIO FORTUNATO PERUGINI

SCIENTIFIC AFFILIATIONS

ITALIAN ASSOCIATION OF MEDICAL ONCOLOGY – AIOM
EUROPEAN SOCIETY OF MEDICAL ONCOLOGY – ESMO

International journals:

1. Ozel A, Kirdar A, Halefoglu AM, Erturk SM, Karpat Z, **Lo Russo G**, Maldur V, Cantisani V. Cysts of the canal of Nuck: ultrasound and magnetic resonance imaging findings. *J Ultrasound* 2009; 12(3):125-7.
2. **Lo Russo G**, Franchi F, Seminara P. Is CEA Better than CYFRA 21-1 in the Monitoring of Squamous Cell Lung Cancer Progression? *Medical Principles and Practice*. 2011; 20(2):200.
3. Papa A, Rossi L, **Lo Russo G**, Giordani E, Spinelli GP, Zullo A, Petrozza V, Tomao S. Emerging Role of Cetuximab in the Treatment of Colorectal Cancer. *Recent Patents on Anti-Cancer Drug Discovery*. 2012; 7(2):233-47
4. Spinelli GP, Miele E, **Lo Russo G**, Miscusi M, Codacci-Pisanelli G, Petrozza V, Papa A, Frati L, Della Rocca C, Gulino A, Tomao S. Chemotherapy and target therapy in the management of adult high-grade gliomas. *Curr Cancer Drug Targets*. 2012;12(8):1016-31.
5. Spinelli GP, **Lo Russo G**, Miele E, Prinzi N, Tomao F, Antonelli M, Giangaspero F, Stati V, Strudel M, Tomao S. Breast cancer metastatic to the pituitary gland: a case report. *World J Surg Oncol*. 2012;10:137
6. **Lo Russo G**, Accarpio F, Spinelli GP, Miele E, Borrini F, Cerbone L, Stati V, Prinzi N, Strudel M, Sibio S, Tomao S. Subcutaneous metastases from colon cancer: a case report. *J Med Case Rep*. 2012;6(1):212.
7. **Lo Russo G**, Spinelli GP, Tomao S, Rossi B, Frati L, Panici PB, Vici P, Codacci Pisanelli G, Tomao F. Breast cancer risk after exposure to fertility drugs. *Expert Rev Anticancer Ther*. 2013;13(2):149-57.
8. Spinelli GP, **Lo Russo G**, Pacchiarotti A, Stati V, Prete AA, Tomao F, Sciarretta C, Arduin M, Basso E, Chiotti S, Sinjari M, Venezia M, Zoccoli G, Tomao S. A 68-year-old Caucasian man presenting with urinary bladder lymphoepithelioma: a case report. *J Med Case Rep*. 2013 ;7(1):161.
9. Gazzaniga P, Gianni W, Raimondi C, Gradilone A, **Lo Russo G**, Longo F, Gandini O, Tomao S, Frati L. Circulating tumor cells in high-risk nonmetastatic colorectal cancer. *Tumour Biol*. 2013;34(5):2507-9.
10. Gazzaniga P, Raimondi C, Gradilone A, Biondi Zoccai G, Nicolazzo C, Gandini O, Longo F, Tomao S, **Lo Russo G**, Seminara P, Vincenzi B, Chimenti I, Cristofanilli M, Frati L, Cortesi E. Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff? *J Cancer Res Clin Oncol*. 2013;139(8):1411-6.
11. Tomao F, Papa A, Rossi L, Strudel M, Vici P, **Lo Russo G**, Tomao S. Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach. *J Exp Clin Cancer Res*. 2013;32:48.
12. Rossi L, Tomao F, **Lo Russo G**, Papa A, Zoratto F, Marzano R, Basso E, Giordani E, Verrico M, Ricci F, Pasciuti G, Francini E, Tomao S. Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study. *Ther Clin Risk Manag*. 2013;9:457-62.
13. Rossi L, Vakiarou F, Zoratto F, Bianchi L, Papa A, Basso E, Verrico M, **Lo Russo G**, Evangelista S, Rinaldi G, Perrone-Congedi F, Spinelli GP, Stati V, Caruso D, Prete A, Tomao S. Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). *Cancer Manag Res*. 2013;5:377-385
14. Tomao F, Papa A, Strudel M, Rossi L, **Lo Russo G**, Benedetti Panici P, Ciabatta FR, Tomao S. Investigating Molecular Profiles of Ovarian Cancer: An Update on Cancer Stem Cells. *J. Cancer* 2014; 5(5): 301-310.
15. Tomao F, **Lo Russo G**, Spinelli GP, Tomao F. Clinical use of fertility agents and risk of breast cancer: a recent update for an old problem. *Curr Opin Obstet Gynecol* 2014, 26(3):130-137. (First name, equal contribute to the first author).
16. *Spinelli GP, Stati V, Prete AA, **Lo Russo G**, Miele E, Sinjari M, Chiotti MS, Ciabatta FR, Rossi B, Tomao S. Bevacizumab in glioblastomas: lights and shadows. *Reviews in Oncology* 2013; 1 (4): 123-133.
17. Tomao F, **Lo Russo G**, Spinelli GP, Stati V, Prete AA, Prinzi N, Sinjari M, Vici P, Papa A, Chiotti MS, Benedetti Panici P, Tomao S. Fertility drugs, reproductive strategies and ovarian cancer risk. *J Ovarian Res*. 2014;7:51. eCollection 2014. (First name, equal contribute to the first author).
18. Zoratto F, Rossi L, Verrico M, Papa A, Basso E, Zullo A, Tomao L, Romiti A, **Lo Russo G**, Tomao S. Focus on genetic and epigenetic events of colorectal cancer pathogenesis:

- implications for molecular diagnosis. *Tumour Biol.* 2014;35(7):6195-6206.
19. Tomao F, Papa A, **Lo Russo G**, Zuber S, Spinelli GP, Rossi L, Caruso D, Prinzi N, Stati V, Benedetti Panici P, Tomao S. Correlation between fertility drugs use and malignant melanoma incidence: the state of the art. *Tumour Biol* 2014; 35:8415-8424. (First name, equal contribute to the first author).
 20. **Lo Russo G**, Tomao F, Spinelli GP, Prete AA, Stati V, Benedetti Panici P, Papa A, Tomao S. Fertility drugs and breast cancer risk. *Eur J Gynaecol Oncol* 2015;36(2):107-13.
 21. *Spinelli GP, Miele E, **Lo Russo G**, Rossi B, Tomao S. *Acrocyanosis, Digital Ischemia and Acronecrosis as First Manifestations of Endometrial Adenocarcinoma: Case Presentation and Literature Review. Int J Gynecol Clin Pract* 2016, 2: 113.
 22. Signorelli D, Macerelli M, Proto C, Vitali M, Cona MS, Agustoni F, Zilembo N, Platania M, Trama A, Gallucci R, Ganzinelli M, Pelosi G, Pastorino U, de Braud F, Garassino MC, **Lo Russo G**. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy? *Tumori* 2016;102(1):18-30.
 23. **Lo Russo G**, Proto C, Garassino MC. Afatinib in the treatment of squamous Non-Small Cell Lung Cancer: a new frontier or an old mistake? *TLCR* 2016 ;5(1):110-4.
 24. Pusceddu S, **Lo Russo G**, Macerelli M, Proto C, Vitali M, Signorelli D, Ganzinelli M, Scanagatta P, Duranti L, Trama A, Buzzoni R, Pelosi G, Pastorino U, de Braud F, Garassino MC. Diagnosis and management of typical and atypical lung carcinoids. *Crit Rev Oncol Hematol* 2016; 100:167-76 (First name, equal contribute to the first author).
 25. **Lo Russo G**, Pusceddu S, Proto C, Lo Russo G, Signorelli D, Vitali M, Ganzinelli M, Gallucci R, Zilembo N, Platania M, Buzzoni R, de Braud F, Marina Garassino MC. Treatment of lung large cell neuroendocrine carcinoma. *Tumour Biol* 2016; 37(6):7047-57.
 26. **Lo Russo G**, Imbimbo M, Garassino MC. Is the chemotherapy era in advanced non-small cell lung cancer really over? Maybe not yet. *Tumori* 2016; (3):223-5.
 27. Pusceddu S, De Braud F, **Lo Russo G**, Concas L, Femia D, Vernieri C, Indini A, Formisano B, Buzzoni R. How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. *Oncotarget*. 2016; 7(28):44841-44847
 28. **Lo Russo G**, Macerelli M, Platania M, Zilembo N, Vitali M, Signorelli D, Proto C, Ganzinelli M, Gallucci R, Agustoni F, Fasola G, de Braud F, Garassino MC. SMALL-CELL LUNG CANCER: CLINICAL MANAGEMENT AND UNMET NEEDS. New perspectives for an old problem. *Curr Drug Targets*. 2016; 18(3):341-362.
 29. Pusceddu S, Femia D, **Lo Russo G**, Ortolani S, Milione M, Maccauro M, Vernieri C, Prinzi N, Concas L, Leuzzi L, De Braud F, Buzzoni R. Update on medical treatment of small intestinal neuroendocrine tumors. *Expert Rev Anticancer Ther* 2016 ; 13:1-8
 30. **Lo Russo G**, Pusceddu S, Prinzi N, Imbimbo M, Proto C, Signorelli D, Vitali M, Ganzinelli M, Maccauro M, Buzzoni R, Seregini E, de Braud F, Garassino MC. Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. *Tumour Biol*. 2016; 37(10):12991-13003.
 31. Imbimbo M, **Lo Russo G**, Blackhall F. Current status of immunotherapy for non-small-cell lung cancer. *Tumori* 2016; 102(4):337-51.
 32. Califano R, Kerr K, Morgan RD, **Lo Russo G**, Garassino M, Morgillo F, Rossi A. Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. *Curr Oncol Rep*. 2016;18(9):59
 33. Vernieri C, Femia D, Pusceddu S, Capella C, Rosai J, Calareso G, Concas L, Prinzi N, **Lo Russo G**, de Braud F, Buzzoni R. Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up. *Case Rep Oncol* 2016, 9(2): 432-439.
 34. Proto C, Imbimbo M, Gallucci R, Brissa A, Signorelli D, Vitali M, Macerelli M, Corrao G, Ganzinelli M, Greco FG, Garassino MC, **Lo Russo G**. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. *TLCR* 2016;5(6):563-578
 35. Pusceddu S, Verzoni E, Prinzi N, Mennitto A, Femia D, Grassi P, Concas L, Vernieri C, **Lo Russo G**, Procopio G. Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. *Ther Adv Med Oncol*. 2017; 9(3):183-188.
 36. Marchianò AV, Cosentino M, Di Tolla G, Greco FG, Silva M, Sverzellati N, Fabbri A, Tamborini E, **Lo Russo G**, Mariani L, Lalli L, Pastorino U. FNA and CNB in the diagnosis of pulmonary lesions: a single-center experience on 665 patients, comparison between two periods. *Tumori*. 2017; 103(4):360-366.
 37. **Lo Russo G**, Imbimbo M, Corrao G, Proto C, Signorelli D, Vitali M, Ganzinelli M, Botta

- L, Zilembo N, de Braud F, Garassino MC. Concomitant EML4-ALK rearrangement and EGFR mutation in non small cell lung cancer patients: A literature review of 100 cases. *Oncotarget*. 2017; 8(35): 59889-59900.
38. Pusceddu S, Prinzi N, **Lo Russo G**, Femia D, Milione M, Perrone F, Tamborini E, Concas L, Pulice I, Vernieri C, Corti F, Buzzoni R, de Braud F. Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. *Future Oncol*. 2017; 13(19):1677-1683.
 39. Proto C, **Lo Russo G**, Corrao C, Ganzinelli M, Facchinetti F, Minari R, Tiseo M, Garassino MC. Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms. *Tumori* 2017; 103(4):325-337
 40. Vitali M, Ripamonti CI, Roila F, Proto C, Signorelli D, Imbimbo M, Corrao G, Brissa A, Rosaria G, de Braud F, Garassino MC, **Lo Russo G**. Cognitive impairment and chemotherapy: a brief overview. *Crit Rev Oncol Hematol*. 2017; 118:7-14.
 41. Metro G, Passaro A, **Lo Russo G**, Bonanno L, Giusti R, Gregorc V, Capelletto E, Martelli O, Cecere FL, Giannarelli D, Luciani A, Bearz A, Tuzi A, Scotti V, Tonini G, Galetta D, Carta A, Soto Parra H, Rebonato A, Morabito A, Chiari R. Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. *Future Oncol*. 2018; 14(4): 353–361.
 42. Galli G, Corrao G, Imbimbo M, Proto C, Signorelli D, Ganzinelli M, Zilembo N, Vitali M, de Braud F, Garassino MC, **Lo Russo G**. Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. *Lung Cancer*. 2018;115:135-142.
 43. Inno A, **Lo Russo G**, Salgarello M, Corrao G, Casolino R, Galli G, Modena A, Romano L, Pusceddu S, Greco FG, Garassino MC, Gori S. The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST. *Tumori* 2018;104(2):88-95. (First name, equal contribute to the first author).
 44. Pusceddu S, Vernieri C, Di Maio M, Marconcini R, Spada F, Massironi S, Ibrahim T, Brizzi MP, Campana D, Faggiano A, Giuffrida D, Rinzivillo M, Cingarini S, Aroldi F, Antonuzzo L, Berardi R, Catena L, De Divitiis C, Ermacora P, Perfetti V, Fontana A, Razzore P, Carnaghi C, Davi MV, Cauchi C, Duro M, Ricci S, Fazio N, Cavalcoli F, Bongiovanni A, La Salvia A, Brighi N, Colao A, Puliafito I, Panzuto F, Ortolani S, Zaniboni A, Di Costanzo F, Torniai M, Bajetta E, Tafuto S, Garattini SK, Femia D, Prinzi N, Concas L, **Lo Russo G**, Milione M, Giacomelli L, Buzzoni R, Delle Fave G, Mazzaferro V, de Braud F. Metformin Use Associates With Longer Progression-free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. *Gastroenterology*. 2018;155(2):479-489.
 45. Garassino MC, Gelibter AJ, Grossi F, Chiari R, Soto Parra H, Cascinu S, Cognetti F, Turci D, Blasi L, Bengala C, Mini E, Baldini EE, Quadri S, Ceresoli GL, Antonelli P, Vasile E, Pinto C, Fasola G, Galetta D, Macerelli M, Giannarelli D, **Lo Russo G**, de Marinis F. Italian nivolumab expanded access program in nonsquamous non-small-cell lung cancer patients: results in never-smokers and EGFR-mutant patients. A multicentric experience. *Journal of Thoracic Oncology*. 2018; 13(8): 1146-1155. (Corresponding Author).
 46. Pusceddu S, Barretta F, Trama A, Botta L, Milione M, Buzzoni R, De Braud F, Mazzaferro V, Pastorino U, Seregni E, Mariani L, Gatta G, Di Bartolomeo M, Femia D, Prinzi N, Coppa J, Panzuto F, Antonuzzo L, Bajetta E, Brizzi MP, Campana D, Catena L, Comber H, Dwane F, Fazio N, Faggiano A, Giuffrida D, Henau K, Ibrahim T, Marconcini R, Massironi S, Žakelj MP, Spada F, Tafuto S, Van Eycken E, Van der Zwan JM, Žagar T, Giacomelli L, Miceli R; **NEPscore Working Group**. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. *Endocr Relat Cancer*. 2018;25(6):607-618. (NEPscore Working Group).
 47. Fucà G, Galli G, Poggi M, **Lo Russo G**, Proto C, Imbimbo M, Vitali M, Ganzinelli M, Lanti C, Molino G, Stangoni F, Zilembo N, de Braud F, Garassino MC, Signorelli D. Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. *Target Oncol*. 2018;13(6):795-800.
 48. **Lo Russo G**, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, Proto C, Prunerì G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino M. Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-Small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. *Clin Cancer Res*. 2019;25(3):989-999.
 49. Imbimbo M, Ottaviano M, Vitali M, Fabbri A, Leuzzi G, Fiore M, Franceschini D, Pasello

- G, Perrino M, Schiavon M, Pruneri G, Dei Tos AP, Sangalli C, Garassino MC, Berardi R, Alessi A, Calareso G, Petrini I, Scorsetti M, Scotti V, Rosso L, Rea F, Pastorino U, Casali PG, Ramella S, Ricardi U, Abate-Daga L, Torri V, Trama A, Palmieri G, Marino M, Zucali PA; **TYME network collaborators**. Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). *Cancer Treat Rev*. 2018 71:76-87. (TYME network collaborators).
50. Garassino MC, Crinò L, Catino A, Ardizzoni A, Cortesi E, Cappuzzo F, Bordi P, Calabrò L, Barbieri F, Santo A, Altavilla G, Ambrosio F, Mini E, Vasile E, Morgillo F, Scoppola A, Bengala C, Follador A, Tedde N, Giannarelli D, **Lo Russo G**, Vitiello F. Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program. *Tumour Biol*. 2018;40(11):1010428318815047. (Corresponding Author).
 51. **Lo Russo G**, Tessari A, Capece M, Galli G, de Braud F, Garassino MC, Palmieri D. MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review. *Front Oncol* 2018;8:650.
 52. Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. *N Engl J Med*. 2018 Dec 6;379(23):2220-2229. (Collaborators).
 53. Boeri M, Milione M, Proto C, Signorelli D, **Lo Russo G**, Galeone C, Verri C, Mensah M, Centonze G, Martinetti A, Sottotetti E, Pastorino U, Garassino MC, Sozzi G. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. *Clin Cancer Res* 2019 doi: 10.1158/1078-0432.CCR-18-1981.
 54. Fucà G, Galli G, Poggi M, **Lo Russo G**, Proto C, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, Torri V, Colombo MP, Vernieri C, Balsari A, de Braud F, Garassino MC, Signorelli D. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. *ESMO Open* 2019;4:e000457.
 55. Spinelli GP, Miele E, Prete AA, **Lo Russo G**, Di Marzo A, Di Cristofano C, Tomao S. Combined surgery and radiotherapy as curative treatment for tracheal adenoid cystic carcinoma: a case report. *J Med Case Rep*. 2019 6;13(1):52.
 56. Platania M, Pasinib F, Porcu L, Boeri M, Verderame F, Modena Y, Del Conte A, Nichetti F, Garassino MC, Martinetti A, Sottotetti E, Cavanna L, Vattermi E, Pozzessere D, Bertolini A, Irtelli L, Verri C, Sozzi G, Protoa C, Pastorino U, Torri V, Fraccon AP, Spinnato F, Signorelli D, **Lo Russo G**, Tuzio A, Gallucci R, Cinieri S, Mencoboni M, Antonelli P, Giacomelli L, de Braud F. Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. *Lung Cancer* 2019; 132: 17–23
 57. Proto C, Ferrara R, Signorelli D, **Lo Russo G**, Galli G, Imbimbo M, Prelaj A, Zilembo N, Ganzinelli M, Pallavicini LM, De Simone I, Colombo MP, Sica A, Torri V, Garassino MC. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): What to add and what to leave out. *Cancer Treat Rev* 2019; 75:39–51
 58. Galli G, Triulzi T, Proto C, Signorelli D, Imbimbo M, Poggi M, Fucà M, Ganzinelli M, Vitali M, Palmieri D, Tessari A, de Braud F, Garassino MC, Colombo MP, **Lo Russo G**. Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. *Lung cancer* 2019
 59. Crinò L, Bidoli P, Delmonte A, Grossi F, De Marinis F, Ardizzoni A, Vitiello F, **Lo Russo G**, Parra HS, Cortesi E, Cappuzzo F, Calabrò L, Tiseo M, Turci D, Gamucci T, Antonelli P, Morabito A, Chella A, Giannarelli D, Galetta D. Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. *Oncologist*, 2019

Book Chapters:

- 1.*Spinelli GP, **Lo Russo G**, Stati V, Tomao S. *Trattamento di prima linea con FOLFOX4 + Cetuximab in paziente con neoplasia del colon-retto metastatica K-Ras wild type. Terapia del carcinoma metastatico del colon-retto: evidenze cliniche. ELSEVIER Srl 2012.*
- 2.*Spinelli GP, **Lo Russo G**, Stati V, Prinzi N, Strudel M, Tomao S. *Gestione complicata del*

Breakthrough pain in un paziente con neoplasia del colon metastatica. Disposizioni per garantire l'accesso alle cure palliative ed alla terapia del dolore, dalla legge 38/2010 alla pratica clinica. Content ed Net Srl 2012.

PAPERS NON INDEXED FOR MEDLINE *

ORAL PRESENTATIONS

- Roma 15/04/2011. *Gliomi di alto grado: dati consolidati e prospettive future.*
- Latina 15/06/2011. *Il cancro del retto: modello di integrazione multidisciplinare.*
- Latina 23/03/2012. *XVIII incontro oncologico pontino. Integrazione tra ospedale e territorio nella gestione clinica del malato oncologico.*
- Aprilia 12/03/2014. *Meeting Oncologici Apriliani 2014. Attualità nelle neoplasie polmonari non a piccole cellule (NSCLC): dalla diagnosi ai target terapeutici.*
- Aprilia 11/06/2014. *Meeting Oncologici Apriliani 2014. Terapie di supporto e qualità di vita: obiettivi ed organizzazione per un programma condiviso.*
- Milano, 19/04/2016. *Fondazione IRCCS Istituto Nazionale dei Tumori . Insieme per le neoplasie toraciche.... Tra sogno e realtà.*
- Milano 12/05/2016. *Convegno Nazionale Medicina di precisione e target in oncologia.*
- Bari 23-24/06/2016. *INNOVATION IN CLINICAL ONCOLOGY: oncogenomics for diagnosis and treatment.*
- Milano 30/06/2016. *Fondazione IRCCS Istituto Nazionale dei Tumori. Immuno oncologia: stato dell'arte ed update.*
- Vienna WCLC 2016. *Nivolumab in never smoker patients with advanced squamous NSCLC: results from the Italian Expanded Access Programme (EAP).*
- Milano, 19/04/2017. *Fondazione IRCCS Istituto Nazionale dei Tumori. INSIEME PER LE NEOPLASIE TORACICHE ...alla ricerca della miglior strategia*
- Roma 20/05/2017 *"NSCLC EGFRm: Costruire un nuovo percorso a fianco del paziente"*
- Negrar (VR) 23/05/2017 *Corso di Immunoterapia in oncologia.*
- Cuneo 17/11/2017 *Congresso GONO 2017. Tra clinica e ricerca in oncologia: come cambia la pratica clinica .*
- Negrar (VR) 28/11/2017 *Corso di Immunoterapia in oncologia. Carcinoma del Rene e della Vescica1.*
- Bergamo 10/05/2018. *Ottava conferenza annuale DIPO. Il carcinoma polmonare una sfida possibile.*
- Milano 07/11/2018. *LA DIAGNOSTICA MOLECOLARE DAL PUNTO DI VISTA DEL MEDICO ONCOLOGO: QUALE VANTAGGIO PER LA DIAGNOSI E LA TERAPIA DEI PAZIENTI.*
- Milano 21/11/2018. *Focus Farmaci Oncologici Condividere l'Utilizzo Sostenibile. Il ruolo dei test genetici in oncologia per l'identificazione delle popolazioni di "nicchia"*
- Milano 29/11/2018. *From Karnofsky to iRECIST: The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy*
- Milano 10/12/2018. *MECCANISMI DI IMMUNOPRESSIONE NEL MICROAMBIENTE TUMORALE: NON SOLO IMMUNO CHECKPOINT. Hyperprogressive disease: the dark side of immunotherapy.*
- Roma 17/05/2019. *GENOMIC LANDSCAPE OF SOLID TUMORS FROM PRIVATE TO COMMON GENOMIC ALTERATIONS: VALIDATED AND RESEARCH DRIVERS. LUNG CANCER*
- Roma 24/05/2019. *ONCOLOGIA DI PRECISIONE. I nuovi criteri di risposta immunocorrelati (iRECIST): sono sempre adeguati?*

Il sottoscritto Giuseppe Lo Russo

nato a Catanzaro il 30.10.1982, residente a Milano, in Via Ettore Paladini n. 5,
c.a.p. 20133, codice fiscale LRSGPP82R30C352F

Avvalendosi della facoltà concessa dall'art. 46 D.P.R. 28/12/2000 n. 445,
consapevole delle responsabilità penali previste dall'art. 76 del citato D.P.R. per le
ipotesi di falsità in atti e di dichiarazioni mendaci, sotto la propria responsabilità

DICHIARA

Che quanto riportato in questo documento corrisponde a verità

Il sottoscritto acconsente e autorizza al trattamento dei dati coperti e tutelati dalla
legge sulla Privacy italiana e dal GDPR – Regolamento Generale sulla Protezione
Dati, in vigore in tutti i paesi dell'Unione Europea dal 25 maggio 2018

Name Lo Russo Giuseppe

Date 06/06/2019

Signature

